Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 6,734 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Scheduling Clear all
Completed Not applicable Interventional

Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer

NCT00438477
View directory record Official record
Conditions
Breast Cancer
Interventions
Isosulfan Blue, Lymphangiography, Technetium Tc 99m sulfur colloid
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation With the Nicotine Patch: A Pilot Study of Patch Messaging

NCT01287377
View directory record Official record
Conditions
Smoking Cessation
Interventions
Telephone Counseling, Nicotine Patches
Behavioral · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 30, 2026, 11:34 PM EDT
Not listed Phase 4 Interventional

Solriamfetol in Binge Eating Disorder

NCT04602936
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 30, 2026, 11:34 PM EDT
Recruiting Not applicable Interventional

Ripening Approaches for Prompt Induction and Delivery - Sequential Versus Concurrent Dilapan-S and Misoprostol to Achieve Vaginal Delivery (RAPID-DS)

NCT07717502
View directory record Official record
Conditions
Nulliparous Women Who Scheduled for Labor Induction, Pregnancy
Interventions
Sequential Cervical Ripening, Inpatient Combined Cervical Ripening
Combination Product
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 11:34 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY3200882 in Participants With Solid Tumors

NCT02937272
View directory record Official record
Conditions
Solid Tumor
Interventions
LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin, Intensity Modulated Radiotherapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Not applicable Interventional

Practical Application of Accelerated iTBS for MDD

NCT06113575
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder, Recurrent Episode, Severe, Major Depressive Disorder, Recurrent, Moderate
Interventions
NeuroStar TMS
Device
Lead sponsor
Sonder Behavioral Health and Wellness
Other
Eligibility
22 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors

NCT01613430
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Cervical Cancer
Interventions
Coach Training (COACH), Printed Educational Materials (PEM)
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
50 Years to 74 Years
Enrollment
1,106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients

NCT00421512
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Kidney Cancer
Interventions
Bevacizumab and Sunitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2008 · Synced Oct 30, 2026, 11:34 PM EDT
Terminated Phase 1 Interventional Results available

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

NCT02848001
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
CC-90009
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
6
States / cities
Stanford, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 30, 2026, 11:34 PM EDT
Not yet recruiting Not applicable Interventional

Lavender Sandalwood Aromatherapy Study

NCT07737392
View directory record Official record
Conditions
Pain, Mood, Patient Satisfaction, Scheduled Cesarean Sections
Interventions
Lavender-sandalwood aromatherapy tabs
Other
Lead sponsor
Memorial Hermann Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Text-based Interventions to Promote COVID-19 Vaccinations

NCT04800965
View directory record Official record
Conditions
Covid19, Vaccines
Interventions
Patient MyChart Scheduling Link, Patient Educational Video, Enhanced Follow through Message
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 30, 2026, 11:34 PM EDT
Recruiting Phase 2 Interventional

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT07112053
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening

NCT05526872
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Best Practice, Health Education, Interview, Planned Notification, Survey Administration
Other · Behavioral
Lead sponsor
Emory University
Other
Eligibility
50 Years to 74 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 30, 2026, 11:34 PM EDT
Terminated Phase 1 Interventional Results available

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

NCT00928200
View directory record Official record
Conditions
Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase
Interventions
Erwinase, Vincristine, Dexamethasone, Doxorubicin, Cytarabine, Methotrexate, Triple Intrathecal Therapy, Dexrazoxane
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 30, 2026, 11:34 PM EDT
Terminated Phase 3 Interventional Results available

Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

NCT01247207
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Male only
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 11:34 PM EDT
Withdrawn Phase 2 Interventional

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

NCT04044209
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Interventions
AG-120, Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex as Rescue Therapy

NCT05661409
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial of a Supporter-Targeted Intervention to Improve Outcomes in Recent Sexual Assault Survivors

NCT05345405
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Helping Behavior, Help-Seeking Behavior, Stress, Relationship, Social, Sexual Assault, Sexual Violence, Social Interaction
Interventions
Dyadic CARE, Supporter-Only CARE
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
14 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

NCT00085436
View directory record Official record
Conditions
Kidney Cancer
Interventions
Aldesleukin,, autologous tumor cell vaccine, recombinant interferon alfa
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Not applicable Interventional Results available

Lifestyle Program for Obstructive Sleep Apnea With Severe Obesity

NCT05343000
View directory record Official record
Conditions
Obstructive Sleep Apnea, Obesity
Interventions
Home-based pulmonary rehabilitation (PR) system
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Phase 2 Interventional

Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine

NCT05378711
View directory record Official record
Conditions
Selective Mutism, Social Anxiety
Interventions
Fluoxetine
Drug
Lead sponsor
Michigan State University
Other
Eligibility
5 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 30, 2026, 11:34 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Novel Thermal Imaging Technique for Breast Screening

NCT05650086
View directory record Official record
Conditions
Breast Cancer
Interventions
Thermalytix
Device
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 30, 2026, 11:34 PM EDT
Completed Phase 1 Interventional

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

NCT00650572
View directory record Official record
Conditions
Cancer
Interventions
ARRY-380, HER2 inhibitor; oral
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 30, 2026, 11:34 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

NCT05770570
View directory record Official record
Conditions
Overweight, Overweight and Obesity, Overweight or Obesity, Obesity, Obese
Interventions
Counseling, Text Messages, Phone calls, Self-monitoring tools
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
1,889 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:34 PM EDT